Wegovy weight-loss drug maker worth more than Danish GDP

Novo Nordisk's market value exceeds Denmark’s domestic economy on the back of its Wegovy diabetes and obesity drug

This week's share surge on news that Wegovy comes with heart benefit catapulted Novo Nordisk's market capitalisation above €385bn. Picture: Wegovy.com

Novo Nordisk has reached another milestone in its meteoric rise: The market value of the Danish company now exceeds the size of Denmark’s domestic economy.

The shares surged this week in the wake of news that the firm's weight-loss drug Wegovy comes with a heart benefit. The gain catapulted the market capitalisation above 2.87 trillion kroner (€385bn), more than Denmark’s 2022 gross domestic product, and means Novo is vying for the title of Europe’s most valuable company.